Does the 80,000-share RSU grant to Vanda’s SVP involve any purchase price?

The RSU grant to Vanda’s SVP has a stated price per share of $0.00 because it is an equity compensation award, not a cash purchase. Shares are delivered as they vest, subject to continued employment and trading window rules rather than payment of a purchase price.

80,000-share RSU grant to Vanda (VNDA) SVP and General Counsel

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

McGuire Daniel Patrick reported acquisition or exercise transactions in this Form 4 filing.

Vanda Pharmaceuticals reported that SVP, General Counsel and Secretary Daniel Patrick McGuire received a grant of 80,000 shares of common stock underlying a restricted stock unit (RSU) award at no cash cost per share. His direct ownership after the grant is 109,982 common shares.

The RSU award vests in four equal annual installments beginning on June 4, 2027, as long as he remains continuously employed through each vesting date. Vested shares will be delivered on the first permissible trading day on or after each vesting date, making this a routine equity-based compensation grant rather than an open-market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McGuire Daniel Patrick

Role SVP, GC and Secretary

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	80,000	$0.00	--

Holdings After Transaction: Common Stock — 109,982 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 80,000 shares Post-grant holdings: 109,982 shares RSU vesting schedule: 4 equal annual installments

3 metrics

RSU grant size 80,000 shares Common stock underlying RSU award to SVP on June 4, 2026

Post-grant holdings 109,982 shares Total direct common shares held after the transaction

RSU vesting schedule 4 equal annual installments First vesting on June 4, 2027, subject to continued employment

Key Terms

RSU, vesting, First Permissible Trading Day

3 terms

RSU financial

"Represents shares of common stock underlying an RSU award."

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

vesting financial

"The RSU vests in four (4) equal annual installments with the first annual vest taking place on June 4, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

First Permissible Trading Day financial

"Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/08/2026 - 04:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McGuire Daniel Patrick

(Last)

(First)

(Middle)

2200 PENNSYLVANIA AVE. NW

SUITE 300E

(Street)

WASHINGTON

DISTRICT OF COLUMBIA

20037

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vanda Pharmaceuticals Inc. [ VNDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, GC and Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/04/2026		A		80,000⁽¹⁾	A	$0	109,982	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock underlying an RSU award. The RSU vests in four (4) equal annual installments with the first annual vest taking place on June 4, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest.

	/s/ Daniel McGuire	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Vanda Pharmaceuticals (VNDA) report for Daniel Patrick McGuire?

Vanda Pharmaceuticals reported that SVP, General Counsel and Secretary Daniel Patrick McGuire received a grant of 80,000 common shares underlying a restricted stock unit award. The grant is part of his equity compensation and does not involve an open-market stock purchase or sale.

How many Vanda (VNDA) shares does Daniel Patrick McGuire hold after this Form 4 filing?

After the reported RSU grant, Daniel Patrick McGuire directly holds 109,982 shares of Vanda common stock. This figure reflects his total direct ownership following the award and helps investors understand the scale of his ongoing equity stake in the company.

What is the vesting schedule for the 80,000 Vanda (VNDA) RSUs granted to McGuire?

The 80,000 RSUs vest in four equal annual installments starting on June 4, 2027. Each installment requires Daniel Patrick McGuire to remain continuously employed through the relevant vesting date, aligning his long-term incentives with the company’s ongoing performance and retention goals.

When will Vanda (VNDA) deliver shares from Daniel McGuire’s RSU award?

Vanda will deliver vested shares from Daniel McGuire’s RSU award on the first permissible trading day on or after each vesting date. This timing ties settlement to both the vesting schedule and applicable trading windows or company policies governing insider stock transactions.